STING1 and breast cancer: The immune-related prognostic index (IRPI) they constructed shows that patients with high IRPI scores have poorer prognoses, further confirming that cGAS-STING pathway inhibition is a key mechanism driving immune evasion in trastuzumab-resistant breast cancer.